We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has ANIXA BIOSCIENCES INC (ANIX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ANIXA BIOSCIENCES INC is a member of the Medical sector. This group includes 998 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANIXA BIOSCIENCES INC is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANIX's full-year earnings has moved 7.3% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ANIX has returned 45.7% so far this year. Meanwhile, the Medical sector has returned an average of -5.3% on a year-to-date basis. This means that ANIXA BIOSCIENCES INC is performing better than its sector in terms of year-to-date returns.
DBV Technologies S.A. (DBVT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 204.2%.
In DBV Technologies S.A.'s case, the consensus EPS estimate for the current year increased 78.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ANIXA BIOSCIENCES INC is a member of the Medical - Biomedical and Genetics industry, which includes 502 individual companies and currently sits at #89 in the Zacks Industry Rank. On average, stocks in this group have lost 5.2% this year, meaning that ANIX is performing better in terms of year-to-date returns. DBV Technologies S.A. is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to ANIXA BIOSCIENCES INC and DBV Technologies S.A. as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has ANIXA BIOSCIENCES INC (ANIX - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
ANIXA BIOSCIENCES INC is a member of the Medical sector. This group includes 998 individual stocks and currently holds a Zacks Sector Rank of #6. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ANIXA BIOSCIENCES INC is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ANIX's full-year earnings has moved 7.3% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ANIX has returned 45.7% so far this year. Meanwhile, the Medical sector has returned an average of -5.3% on a year-to-date basis. This means that ANIXA BIOSCIENCES INC is performing better than its sector in terms of year-to-date returns.
DBV Technologies S.A. (DBVT - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 204.2%.
In DBV Technologies S.A.'s case, the consensus EPS estimate for the current year increased 78.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ANIXA BIOSCIENCES INC is a member of the Medical - Biomedical and Genetics industry, which includes 502 individual companies and currently sits at #89 in the Zacks Industry Rank. On average, stocks in this group have lost 5.2% this year, meaning that ANIX is performing better in terms of year-to-date returns. DBV Technologies S.A. is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to ANIXA BIOSCIENCES INC and DBV Technologies S.A. as they could maintain their solid performance.